There is a critical need to lower costs and shorten the time it takes to develop cancer drugs for pharmaceutical companies, and we believe that the new PredxBio platform is uniquely poised to address these critical challenges head-on

PITTSBURGH (PRWEB)
April 04, 2023

SpIntellx, the leader in Spatial Biology leveraging Explainable AI for predicting the progression of disease, announced today its rebranding as PredxBio (pronounced, “pre-dix-bio”). The PredxBio platform is designed to empower drug discovery, translation, and clinical trials, initially focusing on immuno-oncology space.

Oncology is the world’s largest and fastest growing therapeutic area and immunotherapies have emerged as a promising option for late-stage cancer patients over the last decade. Immune cells play a pivotal role in detecting and destroying abnormal cells, but cancer cells can sometimes completely evade or even suppress the immune response. A deeper and enhanced understanding of the spatial and temporal heterogeneity in the tumor microenvironment (TME) is needed to establish effective immunotherapy treatments. PredxBio is leading the way to deliver transformative insights into the heterogeneous TME for cancer patients, harnessing the latest advances in Spatial Biology and Explainable AI (xAI) to predict highly accurate responses to therapies.

“We are taking this critical step in our evolution as a Spatial Biology based company to reflect the exciting capabilities we have developed leveraging unbiased spatial analytics and xAI to accelerate biomarker discovery, identify novel drug targets, and design better clinical trials identifying sub-populations of response with significantly greater precision. There is a critical need to lower costs and shorten the time it takes to develop cancer drugs for pharmaceutical companies, and we believe that the new PredxBio platform is uniquely poised to address these critical challenges head-on,” said B. Dusty Majumdar, CEO of PredxBio.

The new PredxBio platform seamlessly integrates multimodal data including spatial proteomics, spatial transcriptomics and brightfield pathology to unravel the hidden circuitries of tumor microenvironment and reveal the complex network biology of cancer. The PredxBio platform performs highly scalable, xAI powered unbiased spatial analyses of multiplex immunofluorescent, mass cytometry, and transmitted light images to enable the generation of actionable insights for accelerating biomarker discovery, identifying novel drug targets and designing better clinical trials to stratify patients cohorts.By delving into organizing principles of spatial intratumor heterogeneity and the spatial relationships between different proteins/nucleotides, PredxBio is able to quantify cell-cell interactions, identify intermediate cell types and states, and automatically discover microdomains, which are repeated spatial arrangements or clusters of diverse cells within the tissue environments. Microdomains are critical to gaining a mechanistic understanding of tumor initiation, tumor progression, and response to therapy.

The PredxBio platform is designed to improve prediction accuracies and drive personalized therapeutic options for selecting optimal therapeutics based on insights into spatial tumor biology of individual patients and their potential outcomes. With the launch of the PredxBio brand, we are positioning the company in Spatial Biology with the truly unique capability of unraveling the hidden biological circuitries of cancer to predict patient outcomes with 90%+ accuracy.

About PredxBio

PredxBio is a Pittsburgh, PA-based scaling-stage company focused on the development of explainable AI-powered spatial analytics software platforms to decipher the complex cancer biology and bend the survival curve for immunotherapy cancer patients. PredxBio’s solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. PredxBio has already completed engagements with early paying customers including pharma partners who are harnessing PredxBio’s solutions to assess treatment response in immunotherapy.

http://www.predxbio.com

Share article on social media or email:

Dr. Jon Feldman, Chief Medical Physicist, Hadassah Medical Center, left, with P-Cure CEO Michael MarashIn P-Cure patient treatment center.

“P-Cure started by designing a patient-centric image guided adaptive positioning system, and has now expanded the offer by providing the most compact full proton therapy system,” said CEO Michael Marash.

SHILAT, Israel (PRWEB)
April 03, 2023

P-Cure announced today clearance of its Adaptive Proton Therapy Solution by the FDA for sales in the USA.

P-Cure, an Israel-based high-med-tech company, has developed affordable proton therapy technology for targeted treatment of cancer with significantly reduced treatment related side effects. Treatment of cancer with proton therapy is considered the gold standard for treating many types of cancer sites with unique clinical capabilities. However, current legacy technology requires 200 tons proton equipment, and with the cost exceeding $50 million per single room (equipment and construction) significantly limits establishment of proton therapy services at most cancer care facilities globally. Until today, only less than 1% of hospitals offer proton therapy to their patients. P-Cure managed to reduce the size and the cost of the proton therapy equipment, enabling establishment of this long-awaited treatment modality virtually in all radiotherapy departments. The P-Cure innovative upright solution is the world’s first FDA approved methodology for patient ready cancer treatment.

“P-Cure started by designing a patient-centric image guided adaptive positioning system, and has now expanded the offer by providing the most compact full proton therapy system that simulates, plans, positions and treats patients with enhanced patient comfort and clinical results, treating all indications with adaptive, personalized proton therapy protocols,” said CEO Michael Marash.

“The possibility to install proton therapy within existing linac treatment rooms opens up a unique marketing opportunity for P-Cure. This radiotherapy replacement market accounts for sales of approximately 1,000 radiation therapy modalities every year. We truly believe that this is a new era of radiation therapy, and a new opportunity for P-Cure to become a market leader in providing the most targeted modality to treat cancer with radiation. The P-Cure solution radically reduces the cost of installing a proton therapy system, eliminating large rotating gantries, allowing for faster installation, and reducing operational costs,” Marash adds.

The FDA clearance has been granted in parallel to announcing the clinical research initiation for the use of the system in treatments of patients in Israel. The company solution will be used by the clinical team of the Hadassah Medical Center under the leadership of Prof. Aron Popovtzer, the study principal investigator and the Head of Oncology Institute at Hadassah. The company collaboration with Hadassah is the first ever established initiative to provide access to Israeli patients to receive this focused treatment in the country saving enormous emotional and financial cost for patients, their families, and the national healthcare system. Until now, eligible Israeli patients have been urged to travel to Europe and the US for months spending at least $140,000 for a single treatment course.

“Uniquely, the Hadassah patients will be treated using a fully operational clinical facility within the P-Cure Clinical Development Center. The site is conveniently located between Tel Aviv and Jerusalem and hosts the world’s most compact proton therapy system, which is installed within the footprint of a standard radiotherapy linac vault. The site is established as a clinical platform of excellence to deliver and develop proton therapy protocols for patients as well as train existing and new customers. This training will enable fast technology adaptation by new treatment providers not familiar with proton therapy. The comprehensive site comprises a fully operational clinically designed proton treatment system, including a compact accelerator, a 360 o gantry-less treatment room, and access to all treatment and delivery planning – all within the space of existing linac vaults,” Marash said.

The company is supported by investors from the US, Canada, Israel and Hong Kong. Among the Israeli investors is Medipress Venture.

Prof. Joseph Press, the Medipress CEO, who previously headed the only Children Hospital in Israel, comments that “The P-Cure achievement shifts the use of Proton Therapy from marginal to mainstream clinical practice allowing virtually all radiotherapy departments to install the solution in existing treatment rooms.” Prof. Press adds that because of the P-Cure solution, the financial barriers are eliminated to adding the proton therapy treatment option at medical facilities world-wide.

The FDA clearance of the P-Cure system is another evidence of the unprecedented impact of Israel in the fight against cancer, saving lives and avoiding suffering for millions of patients in Israel and abroad.

“P-Cure is proud to become a member of the world-wide research community expanding the clinical benefits of proton therapy and demonstrating what is the most cost-effective system available to existing oncology centers,” said Marash.

About P-Cure:

P-Cure, an Israel-based company with operation in the US and China, develops and supplies focused radiotherapy solutions (Proton Therapy) to cancer patients globally. For more information please visit: http://www.p-cure.com

Share article on social media or email:

Bioprocessing Virtual Event Series, April 5, 2023

YORBA LINDA, Calif. (PRWEB)
March 30, 2023

Labroots, the leading scientific social networking website, which offers premier, interactive virtual events and webinars to the scientific community, is delighted to host its Bioprocessing Virtual Event Series scheduled on April 5, 2023. Marking its 5th year, this premier global forum comprises drug discovery and preclinical development, upstream processing, downstream processing, analytical development and quality, cell, gene, and nucleic therapies (novel modalities), and manufacturing track sessions.

Free to attend, the program gathers prominent experts from leading academia and industry institutions, top scientists, and research scholars to present the latest advancements on how to accelerate promising biologics and cell and gene therapies, and improve efficiencies spanning all facets of biopharmaceutical development and production.

The jam-packed agenda showcases over 15 sponsored and educational in-depth presentations with multiple live Q&A sessions spanning optimizing clone selection in cell line development, human-induced pluripotent stem cell expansion in a stirred 3D system and the importance of process monitoring, an automated process analytical platform to enable continuous manufacturing of biologics, antibody purification via the unconventional nucleotide binding site, 3D visualisation and characterisation of downstream bioprocessing structures to inform advanced designs, engineering and reprogramming natural killer cells for immunotherapy of cancer, and how digital bioprocess twins can accelerate process development and enable model predictive control strategies, plus much more!

A few conference highlights include two keynote deliveries and panel presentations:

•     Keynote presentation titled “Gene Therapy Manufacturing” with live Q&A presented by Baley Reeves, PhD, Interim Director, National Center for Therapeutics Manufacturing, Texas A&M Engineering exploring types of vectors for gene therapy and a general process for AAV manufacturing.
•     Keynote presentation titled “High-yield Vesicle Packaged Recombinant Protein Production from E. Coli” with live Q&A delivered by Dan Mulvihill, PhD, Professor, Cell and Molecular Biology, University of Kent.
•     Panel Presentation sponsored by LUMINEX A DiaSorin Company titled “Multiple Biomarker Analysis Made Easy with Luminex Multiplex Applications,” with live Q&A.
•     Panel Presentation titled “N-GLYcanyzer: An Automated Process Analytical Platform to Enable Continuous Manufacturing of Biologics, presented by panelists Shishir P.S. Chundawat, Associate Professor, Department and Biochemical Engineering, and Áron Györgypál, Research Associate, Bioprocessing & Glycomics, Chemical and Biochemical Engineering, at Rutgers University.

“Gene therapy-based medicines have opened new doors for the treatment and cure of genetic disease,” said Baley Reeves, PhD, Interim Director, National Center for Therapeutics Manufacturing, Texas A&M Engineering. “However, a generic manufacturing platform for gene therapy products has yet to be developed. Information sharing via Labroots’ platform will be critical as we shape the future for how therapeutics are made.”

“I will present data about a pioneering expression system developed by my group at the university of Kent that improves yield, speed and efficiencies in the biotechnology industry to create proteins in bacteria,” said Dan Mulvihill, PhD, Professor, Cell and Molecular Biology at the University of Kent. “This new technology enables scientists to reprogram a cell to direct the packaging of specific molecules into a separate structure, known as a vesicle, which is then exported out of the cell. This patented technology will improve efficiencies in creating and storing recombinant proteins, which have a range of uses from antibodies to energy production, and I’m delighted to share this technology via Labroots’ unique platform.”

Produced on Labroot’s robust platform, this online event allows participants to connect seamlessly across all desktop and mobile devices providing a complete educational experience. The interactive environment includes a lobby equipped with a leaderboard and gamification, an auditorium featuring live-streaming video webcasts with live attendee chats during scheduled presentations, an exhibit hall to interact with sponsors highlighting contributions in the field, a poster hall to explore data while engaging in live chat conversations coupled with a poster competition giving your research a competitive edge and lastly, a networking lounge to encourage collaborations with colleagues.

Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program. By attending this event, Continuing Education credit (1 per presentation) can be earned for a maximum of 35 credits.

To register for this free event, click here. Use #LRbioprocessing to follow the conversation and connect with other members of the global Bioprocessing community! Follow bioprocessing-related pages @CellBiology_LR on Twitter and @CellandMolecularBiology.LR on Facebook to connect with our specialist Cell Biology Sciences Writers and stay up to date with the latest Trending News in Cell Biology!

About Labroots

Labroots is the leading scientific social networking website and primary source for scientific trending news and premier educational virtual events and webinars, and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate for amplifying global networks and communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

Share article on social media or email:

“Enclomiphene is truly a game changer for my male patients. The oral capsules are taken 3-6 times per week at home, with minimal, if any side effects,” says Dr. David Mahjoubi.

LOS ANGELES (PRWEB)
March 27, 2023

Dr. David Mahjoubi of the IV Healing Spa specializes in IV vitamin infusions, IV ketamine infusions, men’s sexual wellness and peptide therapy for health optimization. For male patients, one of the biggest concerns with aging is an eventual decline in testicular function, and, as a result, lower serum testosterone levels. The symptoms caused by clinically low testosterone levels include erectile dysfunction, low libido, osteoporosis, increased fat mass and decreased muscle mass, which can significantly reduce the quality of life. Enclomiphene is a unique formulation, possessing rapid action and moderate potency to treat male hypogonadism, also known as testosterone deficiency, which is a failure of the testes to produce the male sex hormone testosterone, sperm, or both. Men don’t necessarily have to have hypogonadism for this to work, as the medication can also help men with normal testosterone levels suffering from low libido or those who simply want to feel “optimized.” Unlike testosterone replacement therapy (TRT), enclomiphene doesn’t shut down testosterone production, it increases testosterone by stimulating hormones and does not impact a man’s fertility. In fact, it can increase sperm count and help with pregnancy rates for couples that are struggling. Enclomiphene therapy can also help bodybuilders with increased strength and muscle mass without the side effects of TRT. It may not increase testosterone as much as TRT, but at the same time, the medication does not have the side effects, such as increased aggression, low sperm count and erectile dysfunction. For those interested in enclomiphene, an in-person appointment is not required with Dr. Mahjoubi. Patients simply fill out an online medical health questionnaire that is reviewed by the doctor, and the medication is sent directly to the patient.

“Enclomiphene is truly a game changer for my male patients. The oral capsules are taken 3-6 times per week at home, with minimal, if any side effects,” says Dr. David Mahjoubi.

More about Dr. David Mahjoubi:

David Mahjoubi, M.D. is a board-certified anesthesiologist. He earned his medical degree from The Chicago Medical School and completed his residency training at the University of Southern California (USC) and Los Angeles County Medical Center. Dr. Mahjoubi became interested in natural ways to stay optimized early in his career and currently offers methods that are backed by research to stay mentally and physically healthy. For more information, please visit http://www.IVHealingSpa.com, or call/text (310) 526-4138.

Share article on social media or email:

We understand the importance of intellectual property for our clients, and we appreciate having the opportunity to present at this year’s meeting

West Lafayette, Ind. (PRWEB)
March 21, 2023

Improved Pharma will be at the ACS Spring 2023 National Meeting to be held in Indianapolis March 26 – 30, 2023. There are two opportunities to interact with Improved Pharma at this event.

On Monday March 27th is the reception is for the Chemistry and Law Division of ACS, whose purpose is to advance the understanding and application of the intersection between chemistry and relevant statutory, regulatory, and judicial framework. Improved Pharma is pleased to be a sponsor for this event. The reception takes place from 6:00 – 8:00 PM in room 239 at the Indiana Convention Center and is open to all attendees of the national meeting.

On March 28th, Pamela Smith, Vice President and COO of Improved Pharma will be presenting “Microspectroscopy in art conservation and archaeology: Early applications from the MML” in the Science in Support of Technical Art History session. Her presentation takes place at 8:05 AM in room 122 at the Indiana Convention Center. Dr. Smith’s invited presentation opens the special session for the Division of the History of Chemistry. She will discuss how infrared, Raman, and visible microspectroscopy were used to identify pigments, dyes, binders, fibers, and other organic components in various paintings, fabrics, and manuscripts.

“We are pleased to be able to contribute to the ACS Spring 2023 National meeting, where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge”, remarked Sally Byrn, CEO of Improved Pharma. “We understand the importance of intellectual property for our clients, and we appreciate having the opportunity to present at this year’s meeting.”

About Improved Pharma

Improved Pharma is a research, consulting, and information company dedicated to improving pharmaceutical methods, formulations, and processes. Services include solid-state form studies, formulation design, synchrotron techniques, analytical testing, and expert consulting for the development and defense of intellectual property matters. The company was founded in 2006 by Stephen and Sarah Byrn, who also founded SSCI.

For more information about Improved Pharma’s services, please contact us at 1-765-463-9951 or info@improvedpharma.com.

Share article on social media or email:

FireflySci Cuvette

We are proud to have reached this milestone after ten years of providing excellent customer service and quality products.

NORTHPORT, N.Y. (PRWEB)
March 17, 2023

Fireflysci, a leading provider of quartz cuvettes and other laboratory products, is celebrating a major milestone – 10 years of success selling quartz cuvette products. Founded in 2010, the company has grown to become one of the most trusted sources of quartz cuvettes and related laboratory supplies.

“We are proud to have reached this milestone after ten years of providing excellent customer service and quality products,” said CEO Sim Woitovich. “It is an honor to be able to serve our customers and help them achieve their goals.”

Quartz cuvettes are essential for many scientific experiments and research projects, as they allow researchers to observe light absorbance or transmittance in samples without contamination from outside sources. A Firefly quartz cuvette is also known for its durability, making them ideal for a variety of applications.

For the past decade, Fireflysci has been dedicated to providing its customers with the highest quality glass and quartz cuvettes at competitive prices. The company offers a wide range of sizes and styles, including standard rectangular shapes, semi-micro rectangular shapes, and micro-volume square shapes. All Fireflysci products are made out of the highest quality synthetic quartz glass that has been certified free from optical distortions.

“Our customers trust us to provide them with the highest quality quartz cuvettes on the market,” said Sim. “We take great pride in knowing we have helped researchers around the world make new discoveries.”

The company also offers additional laboratory supplies such as capillary tubes, test tubes, pipettes, and more. As part of its 10th-anniversary celebration, Fireflysci is offering special discounts on select products throughout the year for its loyal customers.

“We are grateful for our customers who have supported us over these past ten years,” said Sim. “We look forward to continuing our commitment to providing excellent customer service and top-notch products.”

Share article on social media or email:

Laboratory Automation, March 22, 2023

YORBA LINDA, Calif. (PRWEB)
March 16, 2023

Labroots, the leading scientific social networking website, offering premier, interactive virtual events and webinars, is delighted to host its 7th annual Laboratory Automation event on March 22, 2023. This free online event brings together thousands of research scholars, laboratory managers, scientists, and experts from leading academic and industry institutions globally to explore disciplines with emerging topics ranging from microfluidics: current and upcoming technologies, automation and new methods to achieve it, and compliance with laboratory software, LIMS and automation, and cyber security.

The informative agenda comprises over a dozen presentations discussing the latest advancements regarding instrumentation and methodologies used to increase the efficiency and effectiveness of research in the lab. Participants will learn from renowned speakers sharing their direct insights on cost-effective automation of common ELISA assays, how and informatics tool, such as a LIMS, can help secure sensitive data and prevent cyberattacks, the role of a LIMS in a quality management system, microfluidics in single cell applications, microfluidics platforms for high throughput in vivo screening, the advantages and disadvantages of the SIFT technology, optimize your PCR, and much more.

Conference highlights span keynote and sponsored talks (not limited to):

• A lively Q&A session, following the presentation sponsored by GenScript, titled, “Automated Tolls to Achieve Consistency, Reliability and Efficiency for Plasmid and Protein Purification, Western Blotting, and Cell Isolation.”
• Panel Presentation sponsored by Thermo Fisher Scientific on Enzymes for Advancing Point of Care Diagnostics and the best enzymes and products for PCR-and isothermal-based assays.
• Panel Presentation sponsored by eLabNext on Lab Automation – Taking Lab Digitization to the Next Level, with live Q&A.
• Panel Presentation sponsored by Opentrons exploring Lab Automation and Community Tools to Support Global Science, with live Q&A.
• Two keynote deliveries with lively Q&A sessions from these stellar presenters: Dino Di Carlo, PhD, Professor of Bioengineering at UCLA, discussing the importance of probing cellular functions, such as single-cell secretions, and Benjamin Yellen, PhD, Co-Founder, CEO at Celldom exploring live single cell biology at ultra-high throughput for applications in T Cell potency and small molecule drug testing.

“We have developed a powerful new tool in our lab-on-a-particle technology that allows us to capture cells and analyze their secretions in unprecedented detail,” said Dino Di Carlo, Professor of Bioengineering at UCLA. “With our 3D-shaped hydrogel microparticle platforms, we can sort cells based on their secreted products and use this information to discover new antibodies, develop cell lines, and select functional cells for therapies. Our secretion encoded single-cell sequencing (SEC-seq) workflow links the transcriptomes of single cells to their secreted products, enabling us to uncover gene networks associated with high secretion of immunoglobulin G and other key factors. With this technology, we have characterized a unique transcriptionally-defined cluster of mesenchymal stromal cells (MSCs) that secrete higher levels of vascular endothelial growth factor (VEGF), a pro-regenerative growth factor that is thought to drive therapeutic benefit in MSC-based therapeutics. I am excited to share our latest results along with other thought-leaders speaking on Labroots’ platform and discuss the potential for nanovial technology to revolutionize the field of cell therapies,” concluded Di Carlo.

“Techniques for measuring live single cells are essential for surveying the functional diversity cell populations. However, to date it is been challenging to perform time lapse measurements on millions of single cells over the course of many days, which is necessary to find drug resistant cells or to quantify the potency of adoptive T cells against a target antigen,” said Ben Yellen, CEO of Celldom. “In this talk, I will discuss how we have approached this problem by combining microwell technology with high throughput imaging, deep learning-based video classification, and clone retrieval, with the goal of providing a universal platform for future discovery tools and QC workflows for applications in the emerging space of cell and gene therapies.”

Produced on Labroots’ robust platform while connecting across all desktop and mobile devices, the online event encompasses a lobby equipped with a leaderboard and gamification feature, an auditorium hosting live-streaming video webcasts with live attendee chats during scheduled presentations, an exhibit hall highlighting recent contributions and connections in real-time with booth representatives, a poster hall to explore data and engage in live chats with poster authors coupled with a poster competition giving your research a competitive edge, and a networking lounge to encourage collaborations with colleagues.

Labroots is an approved provider of continuing education programs in the clinical laboratory sciences by the ASCLS P. A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education Credit per presentation for a maximum of 30 credits.

To register for the event, click here. Participants can use the official hashtag #LRlabauto to follow the conversation and connect with other members of the Laboratory Automation community! Follow @CellBiology_LR on Twitter and @CellandMolecularBiology.LR on Facebook to connect with our specialist Cell & Molecular Biology Writers and stay up to date with the latest Trending Science News.

About Labroots

Labroots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars, and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

Share article on social media or email:

Scispot – the best tech stack for modern biotech

“We used Scispot to set up our online shop, connect our R&D, operational, and commercial data, and automate repetitive workflows,” said Ponni Anand, IgnyteBio CEO

KITCHENER and ONTARIO (PRWEB)
March 09, 2023

Scispot, the creator of the best tech stack for modern biotech companies, has launched Biotech Store™, an e-commerce add-on for Scispot’s Labsheets, allowing biostartups, CROs, and biotech suppliers to turn their inventory or catalog into a secure online store. Revenue is an essential part of growing a company. However, many biotech companies lack the resources and expertise needed to set up a secure e-commerce platform. Biotech Store is a secure, customizable e-commerce platform that connects Scispot’s Labsheets with a suite of 3rd party apps, including Shopify and WooCommerce. This e-commerce add-on allows companies to seamlessly link their lab and inventory management with an online store on their company website – all from their Scispot account.

“Many of our customers needed a platform to sell their lab products or research services. With Biotech Store, companies can now use Scispot to manage their lab data, production data, inventory, and online store, all in the same platform,” said Guru Singh, Founder and CEO, Scispot.

Scispot updates inventory levels in real-time based on production and sales. When a company produces a product at the bench using a protocol template, Scispot automatically updates inventory levels. The inventory is similarly updated when a customer places an order and when that order is shipped. This real-time, automated inventory management means companies always have up-to-date information on inventory levels so they can track progress and milestones, and forecast production needs.

Scispot’s Biotech Store has been adopted by several reagent manufacturers, human biological sample providers, and microbiome kit suppliers, including IgnyteBio, a prominent provider of human immune samples. “We used Scispot to set up our online shop, connect our R&D, operational, and commercial data, and automate repetitive workflows,” said Ponni Anand, CEO, IgnyteBio. “Having all our data in one platform has made every aspect of our company more efficient.”

Book a demo to see how you can use Scispot to manage all aspects of your biotech company and turn your inventory into an online store.

ABOUT SCISPOT

Scispot is a Y Combinator-backed life science informatics company based in the Kitchener-Waterloo area. Scispot has created the best tech stack to help modern biostartups become efficient, scalable TechBio companies. Scispot’s toolkit makes biotech R&D templatizable and programmable, so companies can automate lab management, centralize data, make workflows repeatable, and comply with regulatory guidelines. To learn more, please visit http://www.scispot.com.

Share article on social media or email: